Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatmentnaïve study

Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious.